Biogen Inc. (NASDAQ:BIIB) Shares Purchased by B. Metzler seel. Sohn & Co. AG

B. Metzler seel. Sohn & Co. AG boosted its stake in Biogen Inc. (NASDAQ:BIIB) by 37.6% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 10,128 shares of the biotechnology company’s stock after purchasing an additional 2,767 shares during the period. B. Metzler seel. Sohn & Co. AG’s holdings in Biogen were worth $1,549,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Lee Danner & Bass Inc. acquired a new stake in shares of Biogen in the fourth quarter valued at $25,000. Larson Financial Group LLC grew its position in Biogen by 640.9% in the 4th quarter. Larson Financial Group LLC now owns 163 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 141 shares in the last quarter. SRS Capital Advisors Inc. purchased a new stake in Biogen during the fourth quarter worth about $33,000. OFI Invest Asset Management acquired a new position in shares of Biogen in the fourth quarter valued at approximately $32,000. Finally, Itau Unibanco Holding S.A. increased its stake in Biogen by 63.8% during the 3rd quarter. Itau Unibanco Holding S.A. now owns 231 shares of the biotechnology company’s stock worth $45,000 after buying an additional 90 shares during the period. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Insider Buying and Selling

In related news, Director Stephen A. Sherwin sold 8,760 shares of Biogen stock in a transaction on Friday, March 7th. The stock was sold at an average price of $150.02, for a total transaction of $1,314,175.20. Following the completion of the transaction, the director now directly owns 11,318 shares of the company’s stock, valued at approximately $1,697,926.36. The trade was a 43.63 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. 0.16% of the stock is owned by insiders.

Analysts Set New Price Targets

BIIB has been the subject of several research reports. Jefferies Financial Group downgraded shares of Biogen from a “buy” rating to a “hold” rating and dropped their price target for the stock from $250.00 to $180.00 in a research note on Monday, December 9th. The Goldman Sachs Group cut their price target on Biogen from $281.00 to $245.00 and set a “buy” rating on the stock in a report on Thursday, February 13th. Needham & Company LLC reiterated a “hold” rating on shares of Biogen in a research note on Thursday, February 13th. Sanford C. Bernstein started coverage on shares of Biogen in a report on Tuesday, February 11th. They issued a “market perform” rating and a $160.00 target price on the stock. Finally, Bank of America reiterated a “neutral” rating and issued a $178.00 price target on shares of Biogen in a research note on Tuesday, December 10th. Seventeen investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $213.33.

Biogen Stock Down 0.5 %

BIIB opened at $131.32 on Thursday. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.35 and a quick ratio of 0.90. Biogen Inc. has a 12 month low of $128.51 and a 12 month high of $238.00. The stock has a market capitalization of $19.22 billion, a P/E ratio of 11.74, a P/E/G ratio of 1.51 and a beta of 0.01. The business has a 50 day simple moving average of $141.40 and a 200-day simple moving average of $158.63.

Biogen (NASDAQ:BIIB) last released its earnings results on Wednesday, February 12th. The biotechnology company reported $3.44 EPS for the quarter, beating analysts’ consensus estimates of $3.43 by $0.01. Biogen had a return on equity of 14.98% and a net margin of 16.87%. On average, equities analysts anticipate that Biogen Inc. will post 15.83 earnings per share for the current fiscal year.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.